Logo
x

Search

Subscribe Now

Johnson & Johnson

Johnson & Johnson to Acquire Intra-Cellular Therapies for ~14.6B, Boosting its Neuroscience Portfolio

Johnson & Johnson to Acquire Intra-Cellular Therapies for ~14.6B, Boosting its Neuroscience Portfolio

  • January 14, 2025
Johnson & Johnson’s Reports the CE Mark Approval for Dual Energy Thermocool Smarttouch SF Catheter for Cardiac Arrhythmias

Johnson & Johnson’s Reports the CE Mark Approval for Dual Energy Thermocool Smarttouch SF Catheter for Cardiac Arrhythmias

  • January 13, 2025
Johnson & Johnson Reports the US FDA’s BLA Acceptance of Nipocalimab with Priority Review for Generalized Myasthenia Gravis (gMG)

Johnson & Johnson Reports the US FDA’s BLA Acceptance of Nipocalimab with Priority Review for Generalized Myasthenia Gravis (gMG)

  • January 10, 2025
Johnson & Johnson Reports the EC’s Approval of Rybrevant (Amivantamab) Plus Lazcluze (Lazertinib) as a 1L Treatment of EGFRm NSCLC

Johnson & Johnson Reports the EC’s Approval of Rybrevant (Amivantamab) Plus Lazcluze (Lazertinib) as a 1L Treatment of EGFRm NSCLC

  • December 31, 2024
Johnson & Johnson Submits sBLA to the US FDA for Subcutaneous Induction Regimen of Tremfya (Guselkumab) for Ulcerative Colitis

Johnson & Johnson Submits sBLA to the US FDA for Subcutaneous Induction Regimen of Tremfya (Guselkumab) for Ulcerative Colitis

  • November 25, 2024
Johnson & Johnson to Feature Analysis from P-II (DAHLIAS) Study of Nipocalimab for Treating Sjögren’s Disease at ACR Convergence 2024

Johnson & Johnson to Feature Analysis from P-II (DAHLIAS) Study of Nipocalimab for Treating Sjögren’s Disease at ACR Convergence 2...

  • November 15, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.